UPDATED Jun 17, 2024
Companys with strong funding and high growth potential
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | kr4.70 | 0% | n/a | kr2.7b | kr12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | kr226.00 | -0.7% | -30.3% | kr19.9b | kr369.31 | PS78.9x | E50.9% | 0% | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$1.47 | -12.5% | 19.5% | US$188.5m | US$9.23 | PB1x | E69.8% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$6.29 | -2.6% | 68.6% | US$1.5b | US$13.83 | PS9.2x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | kr21.00 | -10.2% | -30.1% | kr19.9b | kr34.10 | PS79.4x | E50.9% | 0% | Pharmaceuticals & Biotech | ||
LEGN | US$41.50 | -8.9% | -40.8% | US$7.7b | US$82.53 | PS22.1x | E62.9% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
CSPH.F | HK$0.12 | 0% | n/a | HK$1.4b | n/a | PS2.8x | E98.1% | n/a | Pharmaceuticals & Biotech | ||
IVBI.Y | HK$19.48 | 0% | n/a | HK$62.4b | HK$28.22 | PS9.3x | E50.8% | n/a | Pharmaceuticals & Biotech | ||
MSB | AU$1.09 | 4.3% | -6.4% | AU$1.2b | AU$1.10 | PS110.1x | E56.7% | n/a | Pharmaceuticals & Biotech | ||
0JDK | US$8.02 | 3.2% | -1.6% | US$2.3b | US$25.72 | PS1187.5x | E64.9% | n/a | Pharmaceuticals & Biotech | ||
MGTX | US$4.39 | -8.5% | -41.5% | US$288.7m | US$21.20 | PS24.8x | E56.1% | n/a | Pharmaceuticals & Biotech | ||
ACAD | US$14.84 | -0.3% | -38.3% | US$2.5b | US$27.16 | PS3x | E41.8% | n/a | Pharmaceuticals & Biotech | ||
CLRB | US$2.90 | -11.6% | 40.8% | US$115.4m | US$15.25 | PB11.4x | E66.9% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$276.72 | 8.6% | 13.4% | US$5.9b | US$365.07 | PB6.9x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
TVTX | US$7.33 | 0.8% | -57.6% | US$545.8m | US$14.86 | PS3.6x | E67.6% | n/a | Pharmaceuticals & Biotech | ||
SLNO | US$42.49 | -9.7% | 790.8% | US$1.5b | US$67.29 | PB10.8x | E65.2% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$8.13 | -10.3% | -52.8% | US$217.2m | US$23.22 | PS4.2x | E61.3% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$3.68 | -4.9% | -65.0% | US$221.6m | US$9.25 | PB1.9x | E60.0% | n/a | Pharmaceuticals & Biotech | ||
SPRY | US$8.41 | -7.3% | 35.2% | US$839.1m | US$19.00 | PS81488.9x | E58.7% | n/a | Pharmaceuticals & Biotech |